Different areas of health have used growth factors derived from platelets since its first application in 1980, these are concentrated in a first-generation autologous source called platelet rich plasma (PRP). In 1986 Robert Marx was the first to describe the use of PRP for bone grafting in maxillofacial surgery and since then, properties founded on the ability to increase bone regeneration when used in conjunction with bone grafts were attributed. However, the diversity of protocols for their preparation has generated variable results, and the lack of consensus on terminology, characterization and classification, have made it difficult to compare them. Research studies are heterogeneous and the time between the activation of the PRP and the impact of its application in terms of biological effects on cell proliferation, cell cycle and osteogenesis is not completely understood.